Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
Lambert-Eaton myasthenic syndrome (LEMS) is a rare, frequently under-recognized paraneoplastic neurologic disorder that may occur in patients with small cell lung cancer (SCLC). Overlapping features with myasthenia gravis, chemotherapy-induced neuropathy, or deconditioning often delay diagnosis, leading to significant morbidity, functional decline, and missed opportunities to identify SCLC earlier.
This interactive, hybrid satellite symposium was presented in conjunction with the 2025 International Association for the Study of Lung Cancer (IASLC) North America Conference on Lung Cancer (NACLC) in Chicago, Illinois. Using a case-based format, our expert faculty highlight hallmark clinical clues, outline evidence-based diagnostic pathways, and provide strategies for optimizing care with available therapies and multidisciplinary coordination. By addressing real-world challenges in recognition and management, the session aims to equip clinicians with actionable tools to improve outcomes for patients with SCLC and LEMS.
This educational activity is an archive of the live virtual symposium held on December 5, 2025.
Target Audience
This educational activity is directed toward medical oncologists, pathologists, molecular pathologists, thoracic surgeons, and pharmacists involved in the management of patients with SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify distinguishing clinical features of paraneoplastic LEMS that warrant further workup
- Apply a guideline-concordant diagnostic pathway for LEMS that incorporates findings from physical exam, electrodiagnostic studies, antibody testing, and imaging
- Initiate therapy for paraneoplastic LEMS with appropriate consideration for titration and monitoring
- Define best practices for multidisciplinary fast-track pathways with defined roles, referral SLAs, and electromyography access targets
Millie Das, MD
Clinical Professor, Medicine-Oncology
Chief, Oncology
VA Palo Alto Health Care System
Stanford Cancer Institute
Palo Alto, CA
Disclosures: Consultant: Bristol Myers Squibb, Catalyst, EMD Serono, Gilead Sciences, Guardant Health, Janssen, Merus, Natera, Novocure, Regeneron, Sanofi/Genzyme; Grant/Research Support: CellSight Technologies, Genentech, Merck, Novartis, Varian
Wade Iams, MD, MSCI
Director of Lung Cancer Research
Greco Hainsworth Centers for Research
Tennessee Oncology
Nashville, TN
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Guardant Health, Jazz, Merus, Novartis, Novocure, Nuvation Bio, Tempus
Ruham Nasany, MD
Director, Inpatient Neuro Oncology Service
Assistant Professor, Department of Neurology
University of Miami Miller School of Medicine
Aventura, FL
Disclosures: Honoraria Recipient: Janssen Research & Development
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here